ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2818

Differences in the Phenotypic Landscape and Antigen Specificity of CD4+ T Cells Are Present in CCP+ Subjects Before the Onset of Rheumatoid Arthritis

Virginia Muir 1, Cliff Rims 1, Kevin Deane 2, Jeffrey Carlin 3, Sylvia Posso 1, Sunil Nagpal 4, Navin Rao 4, Frédéric Baribaud 5, George Vratsanos 6, William Robinson 7, Gary Firestein 8, V. Michael Holers 9, Peter Linsley 1, Eddie James1 and Jane Buckner 1, 1Benaroya Research Institute, Seattle, WA, 2University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, 3Virginia Mason Medical Center, Seattle, WA, 4Janssen R&D, Spring House, PA, 5Janssen Research & Development, LLC, Spring House, PA, 6JNJ, Raritan, NJ, 7Stanford University, Palo Alto, CA, 8University of California, San Diego, San Diego, 9University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: citrullination, Early Rheumatoid Arthritis, flow cytometry and immune response, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T117: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (2816–2821)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: The “Targeting Immune Responses for Prevention of RA” (TIP-RA) collaboration studies individuals at high risk for developing rheumatoid arthritis (RA) because of serum anti-citrullinated protein antibody (ACPA) positivity in absence of arthritis at baseline, and is focused on defining how they transition from at-risk to classifiable disease. One potential mechanism is the expansion of antigen specific T cells that recognize self-antigens and acquisition of disease associated T cell phenotypes. ACPA emerge years prior to clinically apparent disease and subsequently increase in their titer and breadth of specificity.  However, few studies have characterized T cells during this transition.  Therefore, individuals enrolled in the TIP-RA cohort were analyzed by multi-parameter flow cytometry to identify features associated with progression to RA.

Methods: HLA class II tetramer staining and flow cytometry were performed on peripheral blood samples from a baseline visit from CCP3- controls (n=34), CCP3+ at-risk (n=26), CCP3+ positive individuals who transitioned in the near-term to RA (called “RA converters”, n=4), and seropositive early-RA (n=21).  Our staining panel allowed us to assess the frequencies of T cells specific for citrullinated alpha-enolase, aggrecan, cartilage intermediate layer protein, fibrinogen and vimentin.  We then applied both supervised phenotyping and a cluster-based computational approach to compare the phenotypic landscape and specificity of CD4+ T cells in each cohort.

Results: In comparison with controls, we observed higher frequencies of T cells that recognize citrullinated epitopes in CCP3+ at-risk subjects (p< 0.05), suggesting that these T cells expand prior to disease onset.  Supervised phenotypic analysis revealed an increase in CCR4+ CD4+ T cells in CCP3+ at risk subjects (p< 0.001) and a corresponding decrease in CXCR3+ CD4+ T cells that was most pronounced in RA converters and seropositive early-RA (p< 0.05).  Cluster-based phenotypic analysis revealed a landscape of ten distinct immunophenotypes present within all subjects.  Among these, a CCR4 immunotype was progressively enriched in ACPA+ at risk subjects, RA converters, and seropositive early-RA (p=0.007).  Correspondingly, a CXCR3/CCR4/CCR6 immunotype was progressively depleted in ACPA+ at risk subjects, RA converters, and seropositive early-RA (p=0.05).  Each of these ten immunotypes was shown to contain tetramer positive T cells that recognize citrullinated epitopes.  However, the predominant immunotype varied for different antigens and unique phenotypic patterns were observed for different subject groups.

Conclusion: Our data suggest a progressive change in T cell phenotypes during disease development and subsequent transition to classified RA.  Disease associated changes in the antigen specificity and phenotype of CD4+ T cells are present in CCP3+ at-risk subjects before the onset of symptoms and development of classified RA.  This finding suggests that there is a continuum of immunologic changes that drive disease evolution and that exploring emerging antigen specificities and immunophenotypes will aid our understanding of risk and shape approaches for intervention.


Disclosure: V. Muir, None; C. Rims, None; K. Deane, Bristol-Myers Squibb, 5, Inova, 9, Janssen, 2, 5, Janssen R&D, 2, Microdrop, 5, Pfizer, 2; J. Carlin, None; S. Posso, Janssen, 2; S. Nagpal, Janssen Research & Development, 3, Janssen Research, Johnson&Johnson, 1, 3, 4, Johnson & Johnson, 1, 4; N. Rao, Janssen Research & Development, 3, Johnson & Johnson, 1, 3, 4; F. Baribaud, Janssen Research & Development, LLC, 3; G. Vratsanos, Janssen Research & Development, 1, 3; W. Robinson, None; G. Firestein, Abbvie, 2, Janssen, 2; V. Holers, AdMIRx, 1, 2, 4, 5, 6, Alexion, 7, BMS, 5, Bristol-Myers Squibb, 5, Celgene, 5, Janssen R&D, 2, 5, Pfizer, 2; P. Linsley, None; E. James, Pfizer, 2, Janssen, 2; J. Buckner, Bristol-Myers Squibb, 2, 5, Eli Lilly, 5, Janssen, 2, Novo Nordisk, 2, Pfizer, 2.

To cite this abstract in AMA style:

Muir V, Rims C, Deane K, Carlin J, Posso S, Nagpal S, Rao N, Baribaud F, Vratsanos G, Robinson W, Firestein G, Holers V, Linsley P, James E, Buckner J. Differences in the Phenotypic Landscape and Antigen Specificity of CD4+ T Cells Are Present in CCP+ Subjects Before the Onset of Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/differences-in-the-phenotypic-landscape-and-antigen-specificity-of-cd4-t-cells-are-present-in-ccp-subjects-before-the-onset-of-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differences-in-the-phenotypic-landscape-and-antigen-specificity-of-cd4-t-cells-are-present-in-ccp-subjects-before-the-onset-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology